Alogliptin: A new addition to the class of DPP-4 inhibitors

Radha Andukuri, Andjela Drincic, Marc Rendell

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

Background: Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of DPP-4 elevates levels of the incretin hormones glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) by preventing their degradation. Objective: To review the evolution of alogliptin and its pharmacokinetics, pharmacodynamics, clinical efficacy and adverse effects. In addition, we compared alogliptin to other DPP-4 inhibitors. Methods: A comprehensive literature search was performed using the term 'alogliptin'. Original research articles and review articles as well as scientific abstracts were included. Results: Alogliptin raises postprandial levels of GLP-1. It has excellent bioavailability exhibiting a median Tmax ranging from 1 to 2 hours and a mean half-life of 12.4 to 21.4 hours across all doses. When given as monotherapy, mean hemoglobin A1c (HbA1c) reductions achieved were 0.5% to 0.6%. Combination therapy yielded similar reductions (-0.5% with metformin, -0.6% with glyburide, -0.8% with pioglitazone and -0.6% with insulin). Administration of alogliptin does not promote weight loss but has not resulted in weight gain. The agent is relatively well tolerated with few adverse effects, the major finding being a marginally higher rate of skin events, primarily pruritus. Conclusions: Alogliptin causes significant reductions in HbA1c when used alone or in combination with other oral agents in patients with type 2 diabetes similar to other DPP-4 inhibitors in current clinical use. The side effect profile also does not differ from that of other DPP-4 inhibitors. However, long-term studies are necessary before the place of alogliptin in the management of type 2 diabetes can be established.

Original languageEnglish
Pages (from-to)117-126
Number of pages10
JournalDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Volume2
StatePublished - 2009

Fingerprint

Dipeptidyl-Peptidase IV Inhibitors
Glucagon-Like Peptide 1
pioglitazone
Type 2 Diabetes Mellitus
Hemoglobins
Dipeptidyl Peptidase 4
Incretins
alogliptin
Glyburide
Metformin
Proxy
Pruritus
Hypoglycemic Agents
Biological Availability
Weight Gain
Half-Life
Weight Loss
Pharmacokinetics
Hormones
Insulin

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Internal Medicine

Cite this

Alogliptin : A new addition to the class of DPP-4 inhibitors. / Andukuri, Radha; Drincic, Andjela; Rendell, Marc.

In: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol. 2, 2009, p. 117-126.

Research output: Contribution to journalReview article

Andukuri, Radha ; Drincic, Andjela ; Rendell, Marc. / Alogliptin : A new addition to the class of DPP-4 inhibitors. In: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2009 ; Vol. 2. pp. 117-126.
@article{df1d997bb9274d279e14976d91184497,
title = "Alogliptin: A new addition to the class of DPP-4 inhibitors",
abstract = "Background: Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of DPP-4 elevates levels of the incretin hormones glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) by preventing their degradation. Objective: To review the evolution of alogliptin and its pharmacokinetics, pharmacodynamics, clinical efficacy and adverse effects. In addition, we compared alogliptin to other DPP-4 inhibitors. Methods: A comprehensive literature search was performed using the term 'alogliptin'. Original research articles and review articles as well as scientific abstracts were included. Results: Alogliptin raises postprandial levels of GLP-1. It has excellent bioavailability exhibiting a median Tmax ranging from 1 to 2 hours and a mean half-life of 12.4 to 21.4 hours across all doses. When given as monotherapy, mean hemoglobin A1c (HbA1c) reductions achieved were 0.5{\%} to 0.6{\%}. Combination therapy yielded similar reductions (-0.5{\%} with metformin, -0.6{\%} with glyburide, -0.8{\%} with pioglitazone and -0.6{\%} with insulin). Administration of alogliptin does not promote weight loss but has not resulted in weight gain. The agent is relatively well tolerated with few adverse effects, the major finding being a marginally higher rate of skin events, primarily pruritus. Conclusions: Alogliptin causes significant reductions in HbA1c when used alone or in combination with other oral agents in patients with type 2 diabetes similar to other DPP-4 inhibitors in current clinical use. The side effect profile also does not differ from that of other DPP-4 inhibitors. However, long-term studies are necessary before the place of alogliptin in the management of type 2 diabetes can be established.",
author = "Radha Andukuri and Andjela Drincic and Marc Rendell",
year = "2009",
language = "English",
volume = "2",
pages = "117--126",
journal = "Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy",
issn = "1178-7007",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Alogliptin

T2 - A new addition to the class of DPP-4 inhibitors

AU - Andukuri, Radha

AU - Drincic, Andjela

AU - Rendell, Marc

PY - 2009

Y1 - 2009

N2 - Background: Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of DPP-4 elevates levels of the incretin hormones glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) by preventing their degradation. Objective: To review the evolution of alogliptin and its pharmacokinetics, pharmacodynamics, clinical efficacy and adverse effects. In addition, we compared alogliptin to other DPP-4 inhibitors. Methods: A comprehensive literature search was performed using the term 'alogliptin'. Original research articles and review articles as well as scientific abstracts were included. Results: Alogliptin raises postprandial levels of GLP-1. It has excellent bioavailability exhibiting a median Tmax ranging from 1 to 2 hours and a mean half-life of 12.4 to 21.4 hours across all doses. When given as monotherapy, mean hemoglobin A1c (HbA1c) reductions achieved were 0.5% to 0.6%. Combination therapy yielded similar reductions (-0.5% with metformin, -0.6% with glyburide, -0.8% with pioglitazone and -0.6% with insulin). Administration of alogliptin does not promote weight loss but has not resulted in weight gain. The agent is relatively well tolerated with few adverse effects, the major finding being a marginally higher rate of skin events, primarily pruritus. Conclusions: Alogliptin causes significant reductions in HbA1c when used alone or in combination with other oral agents in patients with type 2 diabetes similar to other DPP-4 inhibitors in current clinical use. The side effect profile also does not differ from that of other DPP-4 inhibitors. However, long-term studies are necessary before the place of alogliptin in the management of type 2 diabetes can be established.

AB - Background: Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of DPP-4 elevates levels of the incretin hormones glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) by preventing their degradation. Objective: To review the evolution of alogliptin and its pharmacokinetics, pharmacodynamics, clinical efficacy and adverse effects. In addition, we compared alogliptin to other DPP-4 inhibitors. Methods: A comprehensive literature search was performed using the term 'alogliptin'. Original research articles and review articles as well as scientific abstracts were included. Results: Alogliptin raises postprandial levels of GLP-1. It has excellent bioavailability exhibiting a median Tmax ranging from 1 to 2 hours and a mean half-life of 12.4 to 21.4 hours across all doses. When given as monotherapy, mean hemoglobin A1c (HbA1c) reductions achieved were 0.5% to 0.6%. Combination therapy yielded similar reductions (-0.5% with metformin, -0.6% with glyburide, -0.8% with pioglitazone and -0.6% with insulin). Administration of alogliptin does not promote weight loss but has not resulted in weight gain. The agent is relatively well tolerated with few adverse effects, the major finding being a marginally higher rate of skin events, primarily pruritus. Conclusions: Alogliptin causes significant reductions in HbA1c when used alone or in combination with other oral agents in patients with type 2 diabetes similar to other DPP-4 inhibitors in current clinical use. The side effect profile also does not differ from that of other DPP-4 inhibitors. However, long-term studies are necessary before the place of alogliptin in the management of type 2 diabetes can be established.

UR - http://www.scopus.com/inward/record.url?scp=77953181717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953181717&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:77953181717

VL - 2

SP - 117

EP - 126

JO - Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

JF - Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

SN - 1178-7007

ER -